跳转至内容
Merck
CN

SML0036

Sigma-Aldrich

Procarbazine hydrochloride

≥98% (HPLC)

别名:

N-(1-Methylethyl)-4-[(2-methylhydrazinyl)methyl]benzamide hydrochloride

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C12H19N3O·HCl
CAS号:
分子量:
257.76
EC 号:
MDL编号:
UNSPSC代码:
12352200
PubChem化学物质编号:
NACRES:
NA.77

质量水平

方案

≥98% (HPLC)

表单

powder

储存条件

desiccated

颜色

white to tan

溶解性

DMSO: ≥18 mg/mL

储存温度

2-8°C

SMILES字符串

Cl.CNNCc1ccc(cc1)C(=O)NC(C)C

InChI

1S/C12H19N3O.ClH/c1-9(2)15-12(16)11-6-4-10(5-7-11)8-14-13-3;/h4-7,9,13-14H,8H2,1-3H3,(H,15,16);1H

InChI key

DERJYEZSLHIUKF-UHFFFAOYSA-N

正在寻找类似产品? 访问 产品对比指南

应用

Procarbazine hydrochloride has been used to study its physicochemical property.
Procarbazine, an antineoplastic alkylating agent, may be used to study its pharmacokinetics, metabolism, safety, efficacy and methods of delivery as an anticancer agent. It may be used to study new combination of anticancer drugs.

生化/生理作用

Procarbazine is an antineoplastic alkylating agent widely used in cancer chemotherapy in combination with other compounds. It has multiple mechanisms of action. Procarbazine inhibits protein, RNA and DNA synthesis in addition to being an alkylating agent.
Procarbazine is metabolized to azoprocarbazine either by cytochrome P450 enzyme and monoamine oxidase in an NADPH (nicotinamide adenine diphosphate) dependent or independent manner. It is considered neurotoxic. Procarbazine is used in combination with therapy for treating Hodgkin′s disease.

象形图

Health hazardExclamation mark

警示用语:

Danger

危险分类

Acute Tox. 4 Oral - Carc. 1B - Muta. 2 - Repr. 1A

储存分类代码

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable


从最新的版本中选择一种:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Marcus Hentrich et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30(33), 4117-4123 (2012-10-10)
Although the outcome of patients with HIV-related Hodgkin lymphoma (HIV-HL) has markedly improved since the introduction of combined antiretroviral therapy, standard therapy is still poorly defined. This prospective study investigates a stage- and risk-adapted treatment strategy in patients with HIV-HL.
Karolin Behringer et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(2), 231-239 (2012-11-15)
To optimize fertility advice in patients with Hodgkin lymphoma (HL) before therapy and during survivorship, information on the impact of chemotherapy is needed. Therefore, we analyzed gonadal functions in survivors of HL. Women younger than age 40 and men younger
Mary R Welch et al.
Neuro-oncology, 14(10), 1304-1311 (2012-09-07)
Up to 20% of all primary CNS lymphoma (PCNLS) patients are aged 80 years or older, yet data are limited on how best to treat this rapidly growing population. Despite demographic pressures and the proven efficacy of methotrexate (MTX)-based regimens
N N Sharkunov et al.
Terapevticheskii arkhiv, 84(11), 71-74 (2012-12-21)
To treat patients with different concurrent cancers, including lympho- and myeloproliferative neoplasms, is a difficult task. The paper presents the experience in successfully treating lymphogranulomatosis occurring in a female patient with chronic myeloid leukemia (CML). A combination of the BEACOPP-14
eIF2alpha phosphorylation is pathognomonic for immunogenic cell death
Bezu L, et al.
Cell Death and Differentiation, 1-1 (2018)

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门